worth buying post Earnings results? PDS Biotechnology (NASDAQ:PDSB)

0
433

Earnings results for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology Corporation is expected* to report earnings on 11/11/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.27. The reported EPS for the same quarter last year was $-1.1.

PDS Biotechnology last issued its earnings data on August 13th, 2020. The reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. PDS Biotechnology has generated ($3.57) earnings per share over the last year. PDS Biotechnology has confirmed that its next quarterly earnings report will be published on Wednesday, November 11th, 2020.

Analyst Opinion on PDS Biotechnology (NASDAQ:PDSB)

4 Wall Street analysts have issued ratings and price targets for PDS Biotechnology in the last 12 months. Their average twelve-month price target is $7.28, predicting that the stock has a possible upside of 244.79%. The high price target for PDSB is $10.00 and the low price target for PDSB is $6.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”

PDS Biotechnology has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $7.28, PDS Biotechnology has a forecasted upside of 244.8% from its current price of $2.11. PDS Biotechnology has only been the subject of 2 research reports in the past 90 days.

Dividend Strength: PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology does not currently pay a dividend. PDS Biotechnology does not have a long track record of dividend growth.

Insiders buying/selling: PDS Biotechnology (NASDAQ:PDSB)

In the past three months, PDS Biotechnology insiders have not sold or bought any company stock. Only 17.78% of the stock of PDS Biotechnology is held by insiders. Only 11.09% of the stock of PDS Biotechnology is held by institutions.

Earnings and Valuation of PDS Biotechnology (NASDAQ:PDSB

Earnings for PDS Biotechnology are expected to grow in the coming year, from ($0.90) to ($0.81) per share. The P/E ratio of PDS Biotechnology is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of PDS Biotechnology is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. PDS Biotechnology has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

More latest stories: here